.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,790,641

« Back to Dashboard

Claims for Patent: 8,790,641

Title:Production of high mannose proteins in plant culture and therapeutic uses thereof
Abstract: A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.
Inventor(s): Shaaltiel; Yoseph (Kibbutz HaSolelim-Doar-Na HaMovil, IL), Baum; Gideon (D.N. Upper Galilee, IL), Bartfeld; Daniel (Moran-Doar-Na Bikat Beit HaKerem, IL), Hashmueli; Sharon (Ramot-Naftali, IL), Lewkowicz; Ayala (Kfar-Vradim, IL)
Assignee: Protalix Ltd. (Carmiel, IL)
Application Number:12/385,894
Patent Claims: 1. A method for treating a subject having Gaucher's disease using exogenous human glucocerebrosidase protein, the method comprising administering a therapeutically effective amount of a glucocerebrosidase protein to said subject, wherein said human glucocerebrosidase protein is as set forth in SEQ ID NO: 15, thereby treating said Gaucher's disease in said subject.

2. The method of claim 1, wherein said human glucocerebrosidase protein is glycosylated with at least one xylose and at least one exposed mannose residue.

3. The method of claim 1, wherein said human glucocerebrosidase protein is glycosylated with at least one core .alpha.-(1,2) xylose and at least one core .alpha.-(1,3) fucose.

4. The method of claim 3, wherein said human glucocerebrosidase protein is glycosylated with at least one exposed mannose residue.

5. The method of claim 1, wherein said human glucocerebrosidase protein is glycosylated with at least one exposed mannose residue and at least one fucose residue having an alpha (1-3) glycosidic bond.

6. The method of claim 2, wherein said xylose residue is a core .alpha.-(1,2) xylose residue.

7. The method of claim 2, wherein said glucocerebrosidase protein binds to a mannose receptor on a macrophage.

8. The method of claim 4, wherein said glucocerebrosidase protein binds to a mannose receptor on a macrophage.

9. The method of claim 7, wherein said glucocerebrosidase is taken up into macrophages.

10. The method of claim 9, wherein said human glucocerebrosidase protein having an increased uptake by said macrophages, in comparison with the corresponding macrophage uptake of a recombinant glucocerebrosidase expressed in mammalian cells.

11. The method of claim 6, wherein the main glycan structure of said therapeutically effective amount of said human glucocerebrosidase protein is glycosylation with one exposed mannose residue.

12. A method of increasing hydrolysis of glycosphingolipid glucocerebroside in macrophages of a subject in need thereof, the method comprising administering a therapeutically effective amount of a human glucocerebrosidase protein to said subject, wherein said human glucocerebrosidase protein is as set forth in SEQ ID NO: 15, thereby increasing hydrolysis of glycosphingolipid glucocerebroside in macrophages of said subject.

13. The method of claim 12, wherein said human glucocerebrosidase protein is glycosylated with at least one xylose and at least one exposed mannose residue.

14. The method of claim 12, wherein said human glucocerebrosidase protein is glycosylated with at least one exposed mannose residue and at least one fucose residue having an alpha (1-3) glycosidic bond.

15. The method of claim 12, wherein the main glycan structure of said therapeutically effective amount of said human glucocerebrosidase protein is glycosylation with one exposed mannose residue.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc